Turn Therapeutics Inc. (NASDAQ:TTRX) Shares Shorted: Short Interest Up 74.1% in September

Posted by Brian Himes on Oct 17th, 2026

Turn Therapeutics Inc. (NASDAQ:TTRX – Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 268,757 shares, an increase of 74.1% from the September 15th total of 154,372 shares. Based on an average trading volume of 201,829 shares, the short-interest ratio is presently 1.3 days. Approximately 0.9% of the shares of the company are short sold.

Turn Therapeutics Price Performance

Shares of Turn Therapeutics stock traded down $1.02 during trading on Friday, hitting $10.57. The stock had a trading volume of 105,614 shares, compared to its average volume of 152,253. The business has a fifty day moving average of $11.60 and a two-hundred day moving average of $7.90. Turn Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $16.45. The firm has a market cap of $314.88 million and a P/E ratio of -36.45. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19.

Turn Therapeutics (NASDAQ:TTRX – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. On average, sell-side analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Turn Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Ieq Capital LLC bought a new stake in shares of Turn Therapeutics in the 2nd quarter valued at approximately $1,660,000. BlackRock Inc. acquired a new position in Turn Therapeutics in the second quarter worth approximately $282,000. Bridgewater Advisors Inc. bought a new position in Turn Therapeutics during the second quarter valued at approximately $242,000. DDFG Inc raised its position in Turn Therapeutics by 34.9% during the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after acquiring an additional 18,246 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in Turn Therapeutics during the second quarter valued at approximately $119,000.

Analyst Ratings Changes

TTRX has been the subject of several recent research reports. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. WBB Securities reiterated a “sell” rating and issued a $10.00 price objective on shares of Turn Therapeutics in a research report on Monday, September 14th. Zacks Research raised shares of Turn Therapeutics to a “hold” rating in a research note on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of Turn Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, October 10th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Turn Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Read Our Latest Stock Report on TTRX

About Turn Therapeutics

(Get Free Report)

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.